Table 1 Patient demographic and clinical characteristics.
Total N = 32 | Low SPHK1 (≤50%) N = 21 | High SPHK1 (>50%) N = 11 | |
|---|---|---|---|
Gender (n = 32) | p = 0.4424 | ||
Male | 21 (65.6%) | 15 (71.4%) | 6 (54.5%) |
Female | 11 (34.4%) | 6 (28.6%) | 5 (45.5%) |
Age at treatment initiation (n = 32) | p = 0.7208 | ||
≤65 years | 13 (40.6%) | 8 (38.1%) | 5 (45.5%) |
>65 years | 19 (59.4%) | 13 (61.9%) | 6 (54.5%) |
Who performance status (n = 31) | p = 1.0000 | ||
0 | 20 (64.5%) | 13 (65.0%) | 7 (63.6%) |
1 | 11 (35.5%) | 7 (35.0%) | 4 (36.4%) |
Missing | 1 | 1 | 0 |
Stage (n = 32) | p = 0.1378 | ||
IIIc | 5 (15.6%) | 5 (23.8%) | 0 (0.0%) |
IV | 5 (15.6%) | 4 (19.0%) | 1 (9.1%) |
IVa | 5 (15.6%) | 4 (19.0%) | 1 (9.1%) |
IVb | 5 (15.6%) | 1 (4.8%) | 4 (36.4%) |
IVc | 12 (37.5%) | 7 (33.3%) | 5 (45.5%) |
Histological subtype (n = 32) | p = 0.5766 | ||
Mucosal | 1 (3.1%) | 1 (4.8%) | 0 (0.0%) |
Cutaneous | 30 (93.8%) | 20 (95.2%) | 10 (90.9%) |
Other | 1 (3.1%) | 0 (0.0%) | 1 (9.1%) |
BRAF (n = 31) | p = 0.1065 | ||
No | 22 (71.0%) | 12 (60.0%) | 10 (90.9%) |
Yes | 9 (29.0%) | 8 (40.0%) | 1 (9.1%) |
Missing | 1 | 1 | 0 |
NRAS (n = 27) | p = 0.4475 | ||
No | 17 (63.0%) | 9 (56.3%) | 8 (72.7%) |
Yes | 10 (37.0%) | 7 (43.8%) | 3 (27.3%) |
Missing | 5 | 5 | 0 |
Treatment line (n = 32) | p = 0.4475 | ||
1 | 23 (71.9%) | 14 (66.7%) | 9 (81.8%) |
2 | 6 (18.8%) | 5 (23.8%) | 1 (9.1%) |
3 | 3 (9.4%) | 2 (9.5%) | 1 (9.1%) |
Treatment line (n = 32) | p = 0.4414 | ||
<2 | 23 (71.9%) | 14 (66.7%) | 9 (81.8%) |
≥2 | 9 (28.1%) | 7 (33.3%) | 2 (18.2%) |
DCI (n = 32) | p = 0.4250 | ||
Pembrolizumab | 22 (68.8%) | 13 (61.9%) | 9 (81.8%) |
Nivolumab | 10 (31.3%) | 8 (38.1%) | 2 (18.2%) |
